CD20Fab-LDM

N/A

Report date: 2025/10/22 16:18:56

Base Information

Drug NameCD20Fab-LDM
Drug Alias NameAnti-CD20 antibody Fab fragment + lidamycin (Institute of Medicinal Biotechnology/Institute of Hematology)Anti-CD20 antibody Fab fragment + lidamycin (Tianjin Chase Sun Pharmaceutical)Anti-CD20 antibody Fab fragment + lidamycin (Chinese Academy of Medical Sciences & Peking Union Medical College)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionDNA intercalatorsB-lymphocyte antigen CD20 inhibitors
TargetsDNAB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInstitute Of Medical Biotechnology, Chinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Chase Sun Pharmaceutical Co Ltd
Inactive CompaniesHematology Hospital Of Chinese Academy Of Medical SciencesInstitute Of Medical Biotechnology, Chinese Academy Of Medical Sciences
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A